Antisense oligonucleotide treatment(Massachusetts General Hospital)

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameAntisense oligonucleotide treatment(Massachusetts General Hospital)
Drug Alias NamenL-TUBB4-001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionTubulin beta-4A chain modulators
TargetsTubulin beta-4A chain
Therapy Area/IndicationsGenetic Diseases, InbornLeukoencephalopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMassachusetts General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts General HospitalUniversity Of California San Diego
Inactive CompaniesN/A
Active IndicationsGenetic Diseases, InbornLeukoencephalopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A